Related Experiment Videos
Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease
1University of Colorado Anschutz Medical Campus , Aurora, CO , USA.
Insights
Autosomal dominant polycystic kidney disease (ADPKD) management in children and young adults benefits from early blood pressure control and renin-angiotensin-aldosterone system blockade. Pravastatin may also help, with other therapies needing further pediatric investigation.
Area of Science:
- Nephrology
- Pediatric Medicine
- Genetics
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent inherited kidney disorder.
- ADPKD carries significant risks for long-term kidney function decline and cardiovascular complications.
- Timely interventions are crucial to mitigate the progressive nature of ADPKD.
Purpose of the Study:
- To review recent clinical trial findings in ADPKD.
- To assess the relevance of these findings for pediatric and young adult populations.
- To explore future therapeutic strategies for ADPKD in younger individuals.
Main Methods:
- Review of recent clinical trial data concerning ADPKD.
- Analysis of therapeutic interventions and their outcomes in children and young adults.
- Consideration of ongoing research and potential future treatments.
Main Results:
- Aggressive blood pressure control using renin-angiotensin-aldosterone system blockade is supported by recent trials.
- Pravastatin therapy shows potential benefits in pediatric and young adult ADPKD patients.
- Several therapies effective in adults require further investigation in younger ADPKD cohorts.
Conclusions:
- Early intervention in ADPKD is vital for managing kidney and cardiovascular health.
- Current evidence supports specific antihypertensive strategies and statin therapy in pediatric ADPKD.
- Further research is necessary to establish the efficacy of other promising ADPKD treatments in children.
Abstract:
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is associated with concerning long-term implications for kidney function and cardiovascular health. Early intervention is needed in order to mitigate these long-term complications. Herein, we review important findings from recent clinical trials in ADPKD and their relevance to affected children and young adults and consider future directions for intervention. Recent clinical trials support aggressive control of blood pressure with blockade of the renin-angiotensin-aldosterone system as well as potential benefit of pravastatin therapy in children and young adults with ADPKD. There are several other candidate therapies, some of which have shown benefit in adult ADPKD, which require further investigation in affected children.